1. Background
=============

Despite advances in medicine and technology, pancreatic cancer surgery is still associated with high postoperativemorbidity. Severe postoperative complications have been reported in the literature to be 15% - 21%after pancreatectomy ([@A13879REF1], [@A13879REF2]). The high rate of complications, while most usually not life threatening, could result in delays in return to intended oncologic therapy, in addition to increased length of stay (LOS)with an associated increase in medical costs ([@A13879REF3]-[@A13879REF5]). With this in mind, there has been an increasing interest in the role of anesthetic techniques in reducing postoperative complications and in the modulation of perioperative inflammation ([@A13879REF6]-[@A13879REF8]).

A volatile gas-opioid based anesthesia and total intravenous anesthesia (TIVA) are two of the common types of general anesthesia used for patients undergoing major abdominal surgery. The choice of anesthetic regimen is typically at the discretion of the attending anesthesiologist and may dependent on their training, experience with various anesthetic agents, or resources available at their practice site. In patients undergoing surgical resection as part of their cancer treatment, mitigating the perioperative inflammatory response and limiting the exposure to opioids thru the use of anesthetic techniques is of increasing interest ([@A13879REF9]). The role of perioperative inflammation,as measured by platelet-lymphocyte ratios (PLR) and neutrophil-lymphocyte ratios (NLR),has been correlated with both postoperative complications and worse oncologic outcomes ([@A13879REF10]-[@A13879REF14]). In a double-blinded randomized study, Sridhar et al found that intravenous lidocaine reduced the stress response and reduced opioid use after abdominal surgery ([@A13879REF15]). Likewise, the anti-inflammatory properties of propofol ([@A13879REF16]), dexmedetomidine ([@A13879REF17]), and ketamine ([@A13879REF18]) have been studied. The role of preemptive analgesia through the use of non-narcotic analgesics and regional anesthesiahas yielded similar positive results on postoperative pain scores and inflammation ([@A13879REF19]-[@A13879REF21]). The anti-inflammatory and opioid reducing properties of these medications have led anesthesiologists to use them in concert through TIVA techniques, with the goal of diminishing the inflammatory response associated with surgery and possibly reduce postoperative complications.

The primary aim of this retrospective study is to evaluate the impact of TIVA on postoperative complications when compared to a volatile-opioid based regimen in patients undergoing pancreatic surgery. The secondary endpoints include analyzing postoperative inflammatory markers and hospital length of stay.

2. Methods
==========

2.1. Study Patient Selection
----------------------------

After approval of the institutional review board (IRB\#: PA13-0223), all adult patients undergoing pancreatic cancer surgery between November 2011 and August 2014 were retrospectively reviewed. Patients were divided in twostudygroups based on the anesthetic regimen (TIVA vs. volatile-opioid anesthesia). Demographics, intraoperative data, postoperative complications and inflammatory markers (NLR and PLR) were collected and analyzed. Complications were prospectively identified and graded during the study period and retrospectively obtained from the institutional pancreatic surgical database. All adverse events that occurred within 90 days of surgery or any complication occurring after 90 days from surgery was included in analysis if the complication was directly related to the surgery ([@A13879REF22]). Adverse events were graded according to the modified accordion severity grading system ([@A13879REF23], [@A13879REF24]).

2.2. Anesthetic Management
--------------------------

The anesthetic technique selection was at the discretion of the attending anesthesiologist. Unless a contraindication existed, all patients were offered an epidural for postoperative analgesia. Epidural catheters were placed in the T7/8 or T8/9 interspaces under strict sterile conditions. In both study groups, epidural catheters were typically bolused at the beginning of surgery with hydromorphone 10 mcg/kg, and then infused with bupivacaine 0.075% with hydromorphone 5 mcg/cc at 8 - 10 cc/hr during surgery.

Patients assigned to the TIVA group received preoperative oral tramadol 300mg, pregabalin 75 mg, celexocib 400mg, unless a contraindication existed. Anesthesia was maintained by total intravenous anesthesia with intraoperative infusions propofol, lidocaine, dexmedetomidine, and ketamine. Maintenance of anesthesia was titrated with the assistance of a bispectral index monitor (BISwith goal range 40 - 60). Goal directed fluid therapy (GDFT) was employed using The Vigileo^®^ (Edwards Lifesciences, Irvine, CA, USA; EV1000) or LiDCOrapid^®^ (LiDCO Group Plc, London, UK) with a target of maintaining stroke volume variation of less than 12.

Patients assigned to the volatile opioid (VO) group received a volatile gas based anesthetic and intravenous opioids. Typically, patients in the VO-group received 1 - 2 mg IV midazolam preoperatively. Induction of anesthesia was typically performed using propofol 2 - 3 mg/kg and fentanyl 1 - 2 mcg/kg. A volatile gas, typically desflurane (3% - 7%), was used for anesthesia maintenance. Intravenous narcotics using fentanyl (50 - 100 mcg boluses) and/or hydromorphone (0.5 - 2 mg boluses) were used for analgesia. GDFT was used at the not routinely used in this group.

2.3. Propensity Matching and Statistical Analysis
-------------------------------------------------

To adjust for selection bias in the observational study, a propensity score matched analysis was created from the eligible patients. The patient pairs were matched based on patient age, gender, epidural use, Charlson comorbidity index ([@A13879REF25]), type of surgery, and length of surgery. A Chi-square test was used to evaluate the association between two categorical variables. Wilcoxon rank sum test was used to evaluate the difference in a continuous variable between patient groups. The repeated measures models were fitted to evaluate the anesthesia technique effect and time effect on inflammatory markers, PLR, and NLR. A P value lower than 0.05 was considered statistically significant. Statistical software SAS 9.3 (SAS, Cary, NC) and S-Plus 8.2 (TIBCO Software Inc., Palo Alto, CA) were used for all the analyses.

3. Results
==========

3.1. Patient and Clinical Characteristics
-----------------------------------------

A total of 366 eligible patient cases were initially identified. Sixty-eight patients were assigned to the TIVA group and 298 assigned to the VO-group. After propensity score matching, 67 matched pairs, a total of 134 total patients, were identified for further analysis. Demographics and clinical characteristics of the matched patient pairs are summarized in [Table 1](#A13879TBL1){ref-type="table"}. All patients in both study groups received an epidural for intraoperative use and postoperative analgesia. There were no major epidural related complications (hematoma or abscess) in either study group. Preoperative hemoglobin was similar (TIVA: 13 ± 1.64 g/dL vs. 12.79 ± 1.93 g/dL; P = 0.394). Patients in the VO group had slightly larger blood loss (783 ± 820 mL) compared to the TIVA group (533 ± 335 mL; P = 0.186), though this was not statistically significant. The VO-group was more likely to be transfused intraoperativelywith packedred blood cells (P = 0.004) and fresh frozen plasma (P = 0.042) than the subjects in the TIVA group. There were no differences in postoperative transfusions (P = 0.594).The urinary output was significantly lower in the VO group (571 ± 331 mL) than in the TIVA group (775 ± 523 mL; P = 0.03).

###### Patient Demographics and Clinical Characteristics^[a](#A13879TBL1FN2){ref-type="table-fn"}^

  Variables                                                             TIVA group (N = 67)   VO-Group (N = 67)
  --------------------------------------------------------------------- --------------------- -------------------
  **Age**                                                               61.3 ± 12.6           61.7 ± 12.7
  **Gender**                                                                                  
  Female                                                                23 (34.3%)            23 (34.3%)
  Male                                                                  44 (65.7)             44 (65.7)
  **ASA classification, No. (%)**                                                             
  2                                                                     6 (9)                 8 (11.9)
  3                                                                     61 (91)               58 (86.6)
  4                                                                     0 (0)                 1 (1.5%)
  **BMI**                                                               27.1 ± 4.3            27.9 ± 5.2
  **Charlson comorbidity index**                                        3.3 ± 1.4             3.3 ± 1.6
  **Preoperative Hemoglobin**                                           13 ± 1.64             12.79 ± 1.93
  **Type of surgery, No. (%)**                                                                
  Pancreaticoduodenectomy                                               49 (73.1)             48 (71.6)
  Distal pancreatectomy                                                 14 (20.9)             16 (23.9)
  Total pancreatectomy                                                  2 (3)                 1 (1.5)
  Combined whipple^[b](#A13879TBL1FN3){ref-type="table-fn"}^            2 (3)                 2 (3)
  **Surgery length, min**                                               449 ± 141             444 ± 169
  **EBL, mL**                                                           533 ± 335             783 ± 820
  Median (range)                                                        450 (100 - 2500)      550 (100 - 4950)
  **Crystalloid, mL**                                                   2765 ± 824            2674 ± 1262
  **Colloid, mL**                                                       1219 ± 583            1378 ± 764
  **Urine output, mL** ^**[c](#A13879TBL1FN4){ref-type="table-fn"}**^   775 ± 523             571 ± 331
  **Intraoperative Transfusions, No. (%)**                                                    
  Packed red blood cells^[c](#A13879TBL1FN4){ref-type="table-fn"}^      8 (11.9)              22 (32.8)
  Fresh frozen plasma^[c](#A13879TBL1FN4){ref-type="table-fn"}^         0 (0)                 4 (6)
  Platelets                                                             1 (1.5)               1 (1.5)
  **Length of stay, days**                                              11.3 ± 4.5            12.9 ± 5.9
  Median (range)                                                        10 (4 - 25)           11 (5 - 36)

Abbreviations: ASA, American Society of Anesthesiologists Physical Classification; BMI, Body Mass Index; EBL, Estimated Blood Loss.

^a^Values are expressed as means and standard deviation, or number and percentages unless specified otherwise.

^b^Combined whipple: patients received whipple operation in addition to either nephrectomy or thoracotomy.

^c^Denotes statistically significant p values (P \< 0.05).

3.2. Perioperative Inflammatory Markers (NLR and PLR)
-----------------------------------------------------

There were no statistical differences (P \> 0.05) in the NLR or PLR between the study groups at any time point both preoperatively and postoperatively ([Figures 1](#A13879FIG1){ref-type="fig"} and [2](#A13879FIG2){ref-type="fig"} respectively).
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3.3. Length of Hospital Stay and Postoperative Complications
------------------------------------------------------------

The mean LOS for the TIVA-group (11.3 ± 4.5 days) was 1 day shorter than in the VO-group (12.9 ± 5.9 days), although this difference was not statistically significant (P = 0.1; [Table 1](#A13879TBL1){ref-type="table"}). Patients in the TIVA group had fewer postoperative adverse events within 90 days of surgery than in the VO group, but not statistically significant. Briefly, 51 (78.5%) of the TIVA group patients compared to 57 (87.7%) in the VO-group (P = 0.161) had an adverse event within 90 days of surgery. There were no statistical differences in complications by organ system identified ([Table 2](#A13879TBL2){ref-type="table"}). The most common complication by organ system in both groups was gastrointestinal complications (TIVA: 39 (60%) vs. VO: 46 (70.8%), P = 0.197). Gastrointestinal complication included pancreatic leak, delayed gastric emptying, gastrojejunostomy leak, hepaticojejunostomy leak, duodenojejunostomy leak, ileus, chyle leak, and unclassified GI complications.

###### Postoperative Complications According to Treatment Group

  Variables                                                                                                       TIVA-Group^[a](#A13879TBL2FN2){ref-type="table-fn"}^   VO-Group^[a](#A13879TBL2FN2){ref-type="table-fn"}^   P Value
  --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------- ---------
  **Patients with adverse events, No. (%)**                                                                       51 (78.5)                                              57 (87.7)                                            0.161
  **Complication by organ system (number of patients), No. (%)** ^**[b](#A13879TBL2FN3){ref-type="table-fn"}**^                                                                                                               
  Gastrointestinal                                                                                                39 (60)                                                46 (70.8)                                            0.197
  Cardiovascular                                                                                                  1 (1.5)                                                1 (1.5)                                              1.000
  Pulmonary                                                                                                       4 (6.2)                                                5 (7.7)                                              1.00
  Renal                                                                                                           0                                                      3 (4.6)                                              0.244
  Hematologic                                                                                                     4 (6.2)                                                3 (4.6)                                              1.000
  Infectious                                                                                                      27 (41.5)                                              29 (44.6)                                            0.723
  Neurologic                                                                                                      0                                                      4 (6.2)                                              0.119
  Metabolic                                                                                                       2 (3.1)                                                1 (1.5)                                              1.000
  Bleeding                                                                                                        12 (18.5)                                              13 (20)                                              0.833
  Other                                                                                                           3 (4.6)                                                8 (12.4)                                             0.206
  **Accordion severity grade** ^**[c](#A13879TBL2FN4){ref-type="table-fn"}**^ **, No. (%)**                                                                                                                                   0.084
  No complication                                                                                                 14 (21.5)                                              8 (12.3)                                             
  1                                                                                                               13 (20)                                                8 (12.3)                                             
  2                                                                                                               24 (36.9)                                              22 (33.8)                                            
  3                                                                                                               9 (13.8)                                               20 (30.8)                                            
  4                                                                                                               2 (3.1)                                                6 (9.2)                                              
  5                                                                                                               2 (3.1)                                                1 (1.5)                                              
  6                                                                                                               1 (1.5)                                                0 (0)                                                
  **Accordion severity grade, No. (%)**                                                                                                                                                                                       
  No Complication, Grades 1,or 2                                                                                  51 (78.5)                                              38 (58.5)                                            0.014
  Grades 3,4,5,or 6                                                                                               14 (21.5)                                              27 (41.5)                                            
  **Average severity score** ^**[d](#A13879TBL2FN5){ref-type="table-fn"}**^                                       0.289 ± 0.184                                          0.323 ± 0.145                                        0.303
  **Postoperative morbidity index (PMI)** ^**[e](#A13879TBL2FN6){ref-type="table-fn"}**^                          0.227± 0.202                                           0.28 ± 0.172                                         0.095
  **Hospital readmission, No. (%)**                                                                               16 (24.6)                                              12 (18.5)                                            0.393

Abbreviation: PMI, Postoperative Morbidity Index.

^a^Two patients each in the TIVA and VO-groups were excluded due to incomplete postoperative complication data (all were combination whipple cases).

^b^Organ system complications include not highest-grade complications.

^c^Modified Accordion severity grading system ([@A13879REF23]), highest grade only.

^d^Average severity score calculated by summing the weights of the highest grade complication for each patient divided by the number of patients who had a complication in each study group.

^e^Calculated by summing the weights of the highest grade complication for each patient divided by the total number of patients in each study group ([@A13879REF26]).

When graded by the modified Accordion Grading Severity System there were no differences (P = 0.084) in complications by severity grade ([Table 2](#A13879TBL2){ref-type="table"}). However, patients in the TIVA-group were more likely to have no complication or a low-grade (grades 1 or 2) complication ([Table 2](#A13879TBL2){ref-type="table"}) compared to the VO-group (P = 0.014). The calculated average severity score for complicated patients was also similar between the study groups (P = 0.303). The difference in calculated postoperative morbidity index (PMI) (TIVA: 0.227 vs. VO: 0.28, P = 0.095) did not reach statistical difference. Hospital readmission rates were comparable between the study groups (TIVA: 16 (24.6%) vs. VO: 12 (18.5%); P = 0.393).

4. Discussion
=============

The choice of the optimal anesthetic regimen should strike a balance between providing adequate pain relief, minimizing complications and length of hospital stay, as well as potentially suppressing inflammatory pathways that could mediate cancer recurrence. Multimodal analgesia consisting of regional anesthesia and an opiate sparing technique has been proven effective in improving short term post-operative outcomes ([@A13879REF27]). In our study, patients who received TIVA were more likely to have no postoperative complication or low-grade complications compared to those patients who received volatile-based anesthesia. These findings however did not correlate with a decreased length of stay. In addition, there was no difference in postoperative inflammatory profiles as measured by NLR or PLR between the study groups.

The concept that the NLR and PLR are biomarkers of immune suppression, systemic inflammation, and a pro-angiogenic state is well studied in the literature ([@A13879REF28]-[@A13879REF30]). These values, NLR and PLR, obtained from common laboratory studies served as markers of inflammation in our analysis. In a study by Haruki et al, the preoperative NLR was independently associated with worse long term outcomes after pancreaticoduodenectomy for carcinoma of the ampulla of vater ([@A13879REF31]). Similarly, preoperative NLR was associated with disease free survival after curative resection for pancreatic adenocarcinoma ([@A13879REF32]). As such, efforts to mitigate inflammation in the perioperative setting are imperative.

Ramirez et al. demonstrated that at clinically relevant concentrations of intravenous lidocaine, natural killer cell function was enhanced ([@A13879REF33]). Intraoperative propofol and dexmedetomidine have been shown to decrease intraoperative levels of interleukins 6 and 8 ([@A13879REF34], [@A13879REF35]). Likewise, the intraoperative use of ketamine has been shown reduce levels of interleukin 6 for several days after a bolus induction dose ([@A13879REF36]). In our study, a TIVA technique was planned to include multiple medications that have proven anti-inflammatory properties. We proposed that by combining these medications in concert, the additive effect would result in a more favorable postoperative inflammatory profile. However, our results do not support this proposition. Perhaps the use of epidural analgesia in all patients may have contributed to lack of differences in NLR and PLR profiles between the study groups. In a prospective randomized trial of patients undergoing Ivor-Lewis esophagectomy, patients who received epidural analgesia had a lower postoperative inflammatory response ([@A13879REF37]). Similar results were reported in knee arthroplasty and spine surgery ([@A13879REF38], [@A13879REF39]). The use of epidural analgesia may potentially result in greater postoperative anti-inflammatory effects than from the use of the aforementioned TIVA medications.

The authors do note limitations to this study. The study was performed retrospectively, so selection biases can exist between the study groups. The authors attempted to minimize selection bias with a propensity score model matching similar patient cases. However, there could have been unaccounted factors that may have influenced the outcomes that were not measured or studied. In addition, the choice of anesthetic regimen (TIVA or VO) was at the discretion of the attending anesthesiologist. A noted difference in the study groups is intraoperative blood transfusion with PRBC and FFP being greater in the VO-group despite statistical similarity in EBL. This may be the result of different transfusion triggers amongst anesthesiologists who perform the VO and TIVA techniques. While adverse events were obtained retrospectively for purposes of this study, the collection of adverse events occurred prospectively and was recorded in the pancreatic surgical database. Despite showing a difference in no complication or lower-grade complication in the TIVA group, perhaps the sample size was inadequate to detect differences in PMI or severity scores between the groups.

In conclusion, patients who received TIVA were more likely to have no complication or lower grade complication when compared to a volatile gas-opioid based anesthetic regimen for pancreatic cancer surgery. However, when graded for severity, the average severity score and postoperative morbidity index was similar. In addition, use TIVA did not result in a difference in postoperative inflammatory profiles. This study demonstrates that future randomized control trials are warranted to further study the optimal anesthetic regimens associated with improved outcomes after pancreatic cancer surgery.
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